摘要
Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95% confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.
| 原文 | English |
|---|---|
| 頁（從 - 到） | 86-92 |
| 頁數 | 7 |
| 期刊 | American Journal of Alzheimer's Disease and other Dementias |
| 卷 | 33 |
| 發行號 | 2 |
| DOIs | |
| 出版狀態 | Published - 2018 三月 1 |
指紋
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health
引用此文
}
Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer’s Disease? A Population-Based Study in Taiwan. / Ku, Li-Jung Elizabeth; Li, Chung-Yi; Sun, Yu.
於: American Journal of Alzheimer's Disease and other Dementias, 卷 33, 編號 2, 01.03.2018, p. 86-92.研究成果: Article
TY - JOUR
T1 - Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer’s Disease? A Population-Based Study in Taiwan
AU - Ku, Li-Jung Elizabeth
AU - Li, Chung-Yi
AU - Sun, Yu
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95% confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.
AB - Although cholinesterase inhibitors (ChEIs) have been proved to help reduce cognitive deterioration in patients with Alzheimer’s disease (AD), their effects on survival remain inconclusive. This study aims to assess the effects of the persistent use of ChEIs on the risk of mortality in patients with AD. This population-based cohort study included 8614 patients having AD with ChEI prescription from 2002 to 2006 and followed until 2010. Kaplan-Meier curves and hazard ratios (HRs) of mortality were estimated in association with ChEI treatment duration and adherence. The average annual mortality rate per 100 person-years was 9.2 for the short-duration group (discontinued < 1 year) and 7.2 for the long-duration group (discontinued ≥ 2 years). Compared to the short-duration group, the long-duration group had a lower mortality (HR = 0.76, 95% confidence interval: 0.69-0.84) and shorter annual inpatient days. But the annual health-care costs did not differ significantly between the 2 groups.
UR - http://www.scopus.com/inward/record.url?scp=85040934431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040934431&partnerID=8YFLogxK
U2 - 10.1177/1533317517734639
DO - 10.1177/1533317517734639
M3 - Article
C2 - 29210284
AN - SCOPUS:85040934431
VL - 33
SP - 86
EP - 92
JO - American Journal of Alzheimer's Disease and other Dementias
JF - American Journal of Alzheimer's Disease and other Dementias
SN - 1533-3175
IS - 2
ER -